Private company

Enfusion, Inc.

American prepackaged software services company based in Chicago2

In its 2025 annual report the company says: “Enfusion is a global, high-growth, software-as-a-service, provider focused on transforming the investment management industry.”6

Last updated Oct 20, 2026.

Overview

$201.6MRevenue, fiscal 20243
$2.8MNet income, fiscal 20243
  • IndustryServices-Prepackaged Software2
  • HeadquartersChicago, United States2
  • Incorporated inDE4
  • Business address125 South Clark Street, Suite 750, Chicago, Il 606034
  • Filer categoryAccelerated filer, Emerging growth company4
  • Legal formLimited Liability Company2
  • LEI549300FNWNZD1BL31B392
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE COMPANY CORPORATION, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 25363962

See how the biggest companies compare on our leaderboards

Enfusion is a global, high-growth, software-as-a-service (“SaaS”), provider focused on transforming the investment management industry. The products and services that comprise our solution are designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. We simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. This allows stakeholders throughout the entire client organization to interact more effectively with one another across the investment management lifecycle.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

67.8%Gross margin3
3.1%Operating margin3
1.4%Net margin3
15.5%Revenue growth, 20243
3.9%Return on equity3
$31.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue32¢$64.9M
  • Other costs65¢$130.4M
  • Income tax2¢$3.5M
  • Profit1¢$2.8M

Out of $201.6M in revenue.3

Where each dollar of operating cash went, fiscal 2024

  • Capital spending10¢$3.6M
  • Kept or used elsewhere90¢$31.0M

Out of $34.7M of cash from operations.3

Financial statements

Revenue7893$201.6M in 2024+242% since 2019
0$100.0M$200.0M$300.0M2019: $59.0M$59.0M20192020: $79.6M$79.6M2020+35%2021: $111.7M$111.7M2021+40%2022: $150.3M$150.3M2022+35%2023: $174.5M$174.5M2023+16%2024: $201.6M$201.6M2024+16%
Gross profit7893$136.7M in 2024+225% since 2019
0$50.0M$100.0M$150.0M2019: $42.1M$42.1M20192020: $58.2M$58.2M2020+38%2021: $79.9M$79.9M2021+37%2022: $103.2M$103.2M2022+29%2023: $116.9M$116.9M2023+13%2024: $136.7M$136.7M2024+17%
Operating income7893$6.2M in 2024−56% since 2019
-$300.0M-$200.0M-$100.0M0$100.0M2019: $13.9M$13.9M20192020: $6.1M$6.1M2020−56%2021: -$275.9M-$275.9M20212022: -$12.0M-$12.0M2022−96%2023: $11.9M$11.9M20232024: $6.2M$6.2M2024−48%
Net income7893$2.8M in 2024−78% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M0$50.0M2019: $12.7M$12.7M20192020: $4.1M$4.1M2020−68%2021: -$158.3M-$158.3M20212022: -$7.7M-$7.7M2022−95%2023: $6.0M$6.0M20232024: $2.8M$2.8M2024−53%
Fiscal year2018201920202021202220232024
Revenue$59.0M7$79.6M8$111.7M9$150.3M3$174.5M3$201.6M3
Cost of revenue$17.0M7$21.4M8$31.8M9$47.1M3$57.6M3$64.9M3
Gross profit$42.1M7$58.2M8$79.9M9$103.2M3$116.9M3$136.7M3
Operating expenses$355.7M9$115.2M3$104.9M3$130.6M3
Operating income$13.9M7$6.1M8-$275.9M9-$12.0M3$11.9M3$6.2M3
Interest$724.0K7$1.7M7$4.6M7
Income before tax-$281.7M9-$12.2M3$11.5M3$7.4M3
Income tax$486.0K7$433.0K8$579.0K9$1.1M3$2.2M3$3.5M3
Net income$12.7M7$4.1M8-$158.3M9-$7.7M3$6.0M3$2.8M3
Earnings per share-$2.269-$0.103$0.073$0.033
Earnings per share (diluted)-$2.269-$0.103$0.073$0.033
Shares (weighted, basic)83.0M shares985.4M shares388.2M shares392.0M shares3
Shares (weighted, diluted)83.0M shares985.4M shares3129.4M shares3129.6M shares3

Compare Enfusion, Inc. with another company

Corporate structure

Enfusion, Inc. sits at the top of its group. 8 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Enfusion, Inc.

  • BROWN CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on Enfusion, Inc., latest May 15, 2025 (6 filings since Oct 11, 2022)
  • ICONIQ Strategic Partners V, L.P. Filed SCHEDULE 13G/A on Enfusion, Inc., latest May 15, 2025 (3 filings since Feb 14, 2022)
  • CSL Tech Holdings LLC Filed SCHEDULE 13G/A on Enfusion, Inc., latest Apr 21, 2025 (2 filings since Feb 14, 2024)
  • LRA Ventures, LLC Filed SCHEDULE 13G/A on Enfusion, Inc., latest Apr 21, 2025 (5 filings since Feb 18, 2022)
  • Malherbe Investments LLC Filed SCHEDULE 13G/A on Enfusion, Inc., latest Apr 21, 2025 (5 filings since Feb 16, 2022)
  • Werner Capital LLC Filed SCHEDULE 13G/A on Enfusion, Inc., latest Apr 21, 2025 (3 filings since Feb 16, 2022)
  • FTV IV, L.P. Filed SCHEDULE 13D/A on Enfusion, Inc., latest Jan 14, 2025 (3 filings since Feb 14, 2022)
  • Dragoneer Investment Group, LLC Filed SC 13G/A on Enfusion, Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Oleg Movchan Filed SC 13G/A on Enfusion, Inc., latest Feb 14, 2023 (3 filings since Feb 14, 2022)
  • HILLHOUSE INVESTMENT MANAGEMENT, LTD. Filed SC 13G on Enfusion, Inc., latest Feb 14, 2022
  • Enfusion, Inc. Chicago, Illinois, United States
    • Enfusion HK Limited Subsidiary · Hong Kong
    • Enfusion Software Limited Subsidiary · Ireland
    • Enfusion Systems UK Ltd Subsidiary · United Kingdom
    • Enfusion Tech Ltd. Subsidiary · United Arab Emirates
    • Enfusion US 1, Inc. Subsidiary · Delaware, United States
    • Enfusion US 2, Inc. Subsidiary · Delaware, United States
    • Enfusion US 3, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Enfusion, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$46.6M3 Dec 31, 2024$35.0M3 Dec 31, 2023+33.1%
Accumulated depreciation$25.7M3 Dec 31, 2024$16.7M3 Dec 31, 2023+53.6%
Property and equipment, net$21.0M3 Dec 31, 2024$18.3M3 Dec 31, 2023+14.5%
Operating-lease assets (leased space)$18.1M3 Dec 31, 2024$14.3M3 Dec 31, 2023+26.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$54.5M3 Dec 31, 2024$35.6M3 Dec 31, 2023+53.0%

Properties, in its own words

We are headquartered in Chicago, Illinois, pursuant to an operating lease that expires in 2030. We lease additional offices in New York City and, internationally, in London, Dublin, Hong Kong, Singapore, Mumbai, Bengaluru, and Sydney. We believe these facilities are generally suitable to meet our current needs. We intend to expand our facilities or add new facilities as we add employees and enter new geographic markets, and we believe that suitable additional or alternative space will be available as needed to accommodate any such growth.

Item 2 of the 10-K filed Mar 3, 2025.6

Leadership

Who has led Enfusion, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas Kim2021–2022
  2. Oleg Movchan2022–now

Chief financial officer

  1. Stephen M. Dorton2021–2022
  2. Bradley Herring2022–now

Chief operating officer

  1. Neal Pawar2023–now
2025
Board members and other officers (17)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Enfusion HK Limited Hong Kong5
  • Enfusion Ltd. LLC Delaware5
  • Enfusion Software Limited The Republic of Ireland5
  • Enfusion Systems UK Ltd England and Wales5
  • Enfusion Tech Ltd. United Arab Emirates5
  • Enfusion US 1, Inc. Delaware5
  • Enfusion US 2, Inc. Delaware5
  • Enfusion US 3, Inc. Delaware5

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Apr 21, 20258-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer34
  2. Apr 17, 20258-K Other events35
  3. Apr 17, 20258-K Shareholder vote36
  4. Apr 11, 20258-K Other events37
  5. Apr 2, 20258-K Other events38
  6. Mar 3, 20258-K Results of operations39
  7. Feb 27, 20258-K Other events40
  8. Jan 13, 20258-K Entered a material agreement; Results of operations; Regulation FD disclosure41
  9. Nov 4, 20248-K Results of operations42
  10. Aug 6, 20248-K Results of operations43
  11. Jul 25, 20248-K Executive or director change44
  12. Jun 18, 20248-K Shareholder vote45
  13. Dec 27, 2022New chief executive Oleg Movchan becomes CEO13
  14. Oct 21, 2021New chief executive Thomas Kim becomes CEO14
  15. Aug 23, 1995Founded Enfusion, Inc. is founded2

Calendar

When it reported results

  1. Mar 3, 2025Reported quarterly or annual results39
  2. Jan 13, 2025Reported quarterly or annual results41
  3. Nov 4, 2024Reported quarterly or annual results42
  4. Aug 6, 2024Reported quarterly or annual results43
  5. May 9, 2024Reported quarterly or annual results46
  6. Mar 12, 2024Reported quarterly or annual results47
  7. Nov 7, 2023Reported quarterly or annual results48
  8. Aug 8, 2023Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

402 filings to the SEC since October 2021: 5 annual reports, 10 quarterly reports, 39 major events, 201 insider forms, 34 large holders, 113 other. The latest 20:

  1. May 15, 2025SCHEDULE 13G/A EDGAR
  2. May 15, 2025SCHEDULE 13G/A EDGAR
  3. May 1, 202515-12G EDGAR
  4. Apr 23, 2025EFFECT EDGAR
  5. Apr 23, 20254 EDGAR
  6. Apr 23, 20254 EDGAR
  7. Apr 21, 202510-K/A EDGAR
  8. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  9. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  10. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  11. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  12. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  13. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  14. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  15. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  16. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  17. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  18. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  19. Apr 21, 20254 OWNERSHIP DOCUMENT EDGAR
  20. Apr 21, 2025SCHEDULE 13G/A EDGAR

The 402 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

76 open-market trades by officers, directors and large owners since October 2021: 2 buys and 74 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 6, 2025CSL Tech Holdings LLC10% ownerSale11,452$11.39$130.4KForm 4
Mar 5, 2025Bastone BronwenChief People OfficerSale3,126$11.38$35.6KForm 4
Mar 5, 2025Campobasso MatthewGeneral CounselSale1,695$11.38$19.3KForm 4
Mar 5, 2025Pawar NealChief Operating OfficerSale14,560$11.38$165.7KForm 4
Mar 5, 2025Gutowski ValeriaChief Accounting OfficerSale542$11.38$6.2KForm 4
Mar 5, 2025Herring BradleyChief Financial OfficerSale4,645$11.38$52.9KForm 4
Mar 4, 2025Gutowski ValeriaChief Accounting OfficerSale1,233$11.37$14.0KForm 4
Mar 3, 2025Gutowski ValeriaChief Accounting OfficerSale219$11.48$2.5KForm 4
Mar 3, 2025Pawar NealChief Operating OfficerSale2,769$11.48$31.8KForm 4
Mar 3, 2025CSL Tech Holdings LLC10% ownerSale2,790$11.48$32.0KForm 4
Mar 3, 2025Herring BradleyChief Financial OfficerSale1,533$11.48$17.6KForm 4
Mar 3, 2025Campobasso MatthewGeneral CounselSale1,081$11.48$12.4KForm 4
Mar 3, 2025Bastone BronwenChief People OfficerSale2,064$11.48$23.7KForm 4
Feb 28, 2025Gutowski ValeriaChief Accounting OfficerSale540$11.42$6.2KForm 4
Jan 13, 2025Somers DeirdreDirectorSale1,637$10.53$17.2KForm 4
Jan 7, 2025Movchan OlegChief Executive OfficerSale2,771$10.13$28.1KForm 4
Jan 7, 2025Herring BradleyChief Financial OfficerSale4,134$10.13$41.9KForm 4
Jan 7, 2025Gutowski ValeriaChief Accounting OfficerSale796$10.13$8.1KForm 4
Jan 7, 2025Campobasso MatthewGeneral CounselSale976$10.13$9.9KForm 4
Jan 7, 2025Bastone BronwenChief People OfficerSale809$10.13$8.2KForm 4

All 76 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Enfusion, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREnfusion, Inc.1
  • CIK0001868912
  • Employer ID (EIN)87-12684626
  • Filer statusAccelerated filer an emerging growth company; not a smaller reporting company; not a shell company6
  • Incorporated inDelaware6
  • Fiscal year endsDecember 311
  • Industry code (SIC)7372 Services-Prepackaged Software1
  • SEC reviewing officeOffice of Technology, Division of Corporation Finance1
  • Business address125 South Clark Street, Suite 750, Chicago, IL 606031
  • Phone(312) 253-98001
  • Shares outstanding129,000,840 Common Stock shares; 94,802,073 Common Class A shares; 34,198,767 Common Class B shares as of Feb 26, 20256
  • Public float$419.3M as of Jun 30, 20246
  • AuditorErnst & Young LLP, Chicago, Illinois PCAOB ID 42; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceJul 1, 20211
  • Filings422 in all: 4 (170), 144 (64), 8-K (39), 3 (25), SC 13G/A (16), 425 (12), 10-Q (10), CORRESP (9)1
    All 37 form types

    SC 13G (9), DEFA14A (8), UPLOAD (8), SCHEDULE 13G/A (7), 10-K (4), 4/A (4), S-8 (4), S-8 POS (4), DEF 14A (3), EFFECT (3), S-1/A (3), 3/A (2), ARS (2), 10-K/A (1), 144/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), S-1 (1), S-3 (1), SC 13D (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2025
    Quarterly report (10-Q) Nov 4, 2024
    Proxy statement (DEF 14A) Apr 26, 2024
    Latest 8-K (8-K) Apr 21, 2025

Securities registered for trading

ClassSymbolExchange
Class A common stock, par value $0.001 per shareENFNNew York Stock Exchange

From the cover page of the 10-K filed Mar 3, 2025 (Section 12(b) of the Exchange Act).6

Risk factors and legal proceedings

The risks Enfusion, Inc. names in Item 1A of its 10-K filed Mar 3, 2025: 56 risks under these headings, as written.6

  • Risks Related to Our Business and Our Industry
  • If the adoption and acceptance of cloud-based financial solutions slows or shifts in a way we do not anticipate or are unable to support or if we do not accurately anticipate, prepare for, and promptly respond to rapidly evolving client needs, our sales will suffer, and the results of our operations will be adversely affected.
  • The Merger, the pendency of the Merger or the Company’s failure to complete the Merger could have a material adverse impact on our business, results of operations, financial condition, or the price of our Class A common stock.
  • If we are unable to develop, introduce and market new and enhanced versions of our solution or are unable to anticipate or respond to evolving technological requirements, we may be put at a competitive disadvantage and our operating results could be adversely affected.
  • We may be unable to maintain our revenue growth rate in the future.
  • If we continue expanding our operations but fail to effectively execute on our growth strategy, our margins and net income may decline, which may harm our business and results of operations.
  • We may have to invest more resources in technology and development than anticipated and our technology and development efforts or spend may prove to be fruitless or unsuccessful, which could increase our operating expenses and negatively affect our results of operations.
  • We may experience quarterly fluctuations in our operating results due to a number of factors, which may make our future results difficult to predict and could cause our operating results to fall below expectations or our guidance.
  • We may not accurately predict the long-term client retention rate or adoption of our solution, or any resulting impact on our revenues or operating results.
  • Cyberattacks or other breaches of our security measures or those we rely on could result in unauthorized access to, use or destruction of confidential or proprietary information, including our clients’ or their clients’ data, which may materially and adversely impact our reputation, business, and results of operations.
  • We depend on third-party co-locate facilities, data centers operated by third parties, and third-party Internet service providers, and any disruption in the operation of such facilities or access to the Internet could adversely affect our business.
  • Actual or perceived defects, errors, or vulnerabilities in our solution, including failures in connection with client market orders, could harm our reputation, result in significant costs to us, impair our ability to sell our solution and subject us to substantial liability.
The other 45 risks
  • We and our clients leverage third-party software, content, connectivity, and services for use with our solution. Performance issues, errors and defects, or failure to successfully integrate or license necessary third-party software, content, connectivity, or services, could cause delays, errors, or failures of our solution, cause reputational harm, increases in our expenses and reductions in our sales, each of which could materially and adversely affect our business and results of operations.
  • Interruptions in the availability of server systems or network or communications with Internet, third-party hosting facilities or cloud-based services, interruptions in the third-party connections utilized by our clients, or failure to maintain the security, confidentiality, accessibility, or integrity of data stored on such systems, could harm our business or impair the delivery of our solution.
  • The markets in which we participate are intensely competitive, and pricing pressure, new technologies, or other competitive dynamics could adversely affect our business and operating results.
  • If we fail to effectively anticipate and respond to changes in the industry in which we operate, our ability to attract and retain clients could be impaired and our competitive position could be harmed.
  • Events affecting the investment management industry could materially and adversely affect us and cause our stock price to decline significantly.
  • If we fail to effectively train our clients to use our solution or fail to provide high-quality implementation, technical support, or managed services, it could have an adverse effect on our reputation and our ability to sell our solution to new clients and retain existing clients or renew agreements with our existing clients.
  • If we are unable to effectively integrate our solution with other systems used by our clients, or if there are performance issues with such third-party systems, our solution will not operate effectively, and our business and reputation will be adversely affected.
  • Our sales cycle and related client implementation, especially with regard to large financial institutions and other institutional or complex client profiles, can be lengthy and variable, depend upon factors outside our control, and could cause us to expend significant time and resources.
  • Our international operations may fail, and we may fail to successfully expand internationally. In addition, sales to clients outside the United States or with international operations expose us to risks inherent to international businesses, which may include adverse impacts arising out of international regulatory changes.
  • Our solution is highly technical, and if we are unable to attract or retain key employees and other skilled personnel that are capable of managing our business strategy or working with our solution, we may be unable to achieve our goals and our business will suffer.
  • Our corporate culture has contributed to our success, and if we cannot maintain it as we grow, we could lose the innovation, creativity and teamwork fostered by our culture, and our business may be adversely affected.
  • Increases in labor costs, including salaries or wages, and an overall tightening of the labor market, could adversely affect our business, results of operations, or financial condition.
  • Global or regional economic and market conditions may negatively impact our business, financial condition, and results of operations.
  • Natural or man-made disasters outside of our control and other similar events may significantly disrupt our business, and negatively impact our business, financial condition, and results of operations.
  • Failure of any of our established systems to satisfy client demands or to maintain market acceptance would harm our business, results of operations, financial condition, and growth prospects.
  • We may acquire or invest in companies, or pursue business partnerships, which may divert our management’s attention or result in dilution to our stockholders, and we may be unable to integrate acquired businesses and technologies successfully or achieve the expected benefits of such acquisitions, investments, or partnerships.
  • If we are unable to effectively manage certain risks and challenges related to our India operations, our business could be harmed.
  • Financial and Accounting Related Risks
  • Our revenue recognition and other factors may create volatility in our financial results in any given period and make them difficult to predict.
  • Our ability to raise capital in a timely manner if needed in the future may be limited, or such capital may be unavailable on acceptable terms, if at all. Our failure to raise capital if needed could adversely affect our business and results of operations, and any debt or equity issued to raise additional capital may reduce the value of our Class A common stock.
  • Our estimates of certain operational metrics are subject to inherent challenges in measurement.
  • We are subject to certain restrictive covenants under agreements relating to our credit facility. In addition, substantially all of our assets, including our intellectual property, are pledged as collateral to secure such credit facility.
  • Risks Related to Our Intellectual Property
  • If we are unable to protect our intellectual property, including trade secrets, or if we fail to enforce our intellectual property rights, our business could be adversely affected.
  • Claims or assertions by third parties of infringement or other violations by us of their intellectual property rights could result in significant costs and substantially harm our business and results of operations.
  • If our solution infringes on the intellectual property rights of others, we may be required to obtain costly licenses, enter into unfavorable royalty agreements, be forced to terminate some clients’ agreements, or indemnify our clients for any or some damages they suffer.
  • We use “open source” software in our solution, which may restrict how we use or distribute our solution, require that we release the source code of certain software subject to open source licenses, or subject us to litigation or other actions that could adversely affect our business.
  • Risks Related to Legal and Regulatory Matters
  • Although we are not subject to the same regulations as our clients, the regulatory environment in which our clients operate is subject to continual change and regulatory developments designed to increase oversight could adversely affect our business.
  • Any future litigation against us could damage our reputation and be costly and time-consuming to defend.
  • Our failure to comply with laws and regulations related to the Internet or future government regulation of the Internet could increase costs and impose constraints on the way we conduct our business.
  • Our failure to comply with the FCPA and similar anti-bribery and anti-corruption laws associated with our activities outside the United States could subject us to penalties and other adverse consequences.
  • Our failure to comply with various data privacy, protection and security regulations could impose additional costs and liabilities on us, limit our use, storage, or processing of information and adversely affect our business.
  • Failure to comply with governmental laws and regulations could harm our business, materially and adversely affect us, and cause our stock price to decline significantly.
  • Risks Related to our Class A Common Stock
  • The market price and trading volume of our Class A common stock may be volatile, which could result in rapid and substantial losses for our stockholders.
  • An active, liquid trading market for our Class A common stock may not develop or be sustained, which may make it difficult for you to sell the Class A common stock you purchase.
  • Future sales of shares by existing stockholders could cause our stock price to decline.
  • Future offerings of debt or equity securities by us may materially and adversely affect the market price of our Class A common stock.
  • The future issuance of additional Class A common stock in connection with our incentive plans or otherwise will dilute all other stockholdings.
  • Insiders have substantial control over us, which could limit your ability to influence the outcome of key transactions, including a change of control.
  • Risks Related to our Organizational Structure
  • Enfusion, Inc. is a holding company, and its only material asset is its direct and indirect interest in Enfusion Ltd. LLC, and it is accordingly dependent upon distributions from Enfusion Ltd. LLC to pay taxes, make payments under the Tax Receivable Agreement, and pay dividends.
  • Enfusion, Inc. will be required to pay certain of our Pre-IPO Owners for most of the benefits relating to tax depreciation or amortization deductions that we may claim as a result of Enfusion, Inc.’s acquisition of existing tax basis in the IPO, increases in existing tax basis and anticipated tax basis adjustments we receive in connection with sales or exchanges (or deemed exchanges) of Common Units or distributions (or deemed distributions) with respect to Common Units after the IPO and our utilization of certain tax attributes of the Blocker Companies.
  • In certain cases, payments under the Tax Receivable Agreement may be accelerated and/or significantly exceed the actual benefits Enfusion Ltd. LLC realizes in respect of the tax attributes subject to the Tax Receivable Agreement.
  • The acceleration of payments under the Tax Receivable Agreement in the case of certain changes of control may impair our ability to consummate change of control transactions or negatively impact the value received by owners of our Class A common stock.
  • General Risk Factors
  • As an “emerging growth company” under the Jumpstart Our Business Startups Act (the “JOBS Act”), we are permitted to, and intend to, rely on exemptions from certain disclosure requirements, which could make our Class A common stock less attractive to investors.
  • As a public company, we are obligated to develop and maintain proper and effective internal control over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our Class A common stock.
  • We incur increased costs and administrative burdens in connection with operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would harm our business.
  • Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to choose the judicial forum for disputes with us or our directors, officers or employees.

Legal proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
    SEC EDGAROther events
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59